下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

CB Scientific, Inc. Enters Beta-testing Phase for Its Updated Proprietary My-Cam Cardiac Event Monitor
CB Science公司的最新专利My-Cam心脏事件监测器进入Beta测试阶段

Accesswire ·  {{timeTz}}

Updates to provide device improvements while maintaining the innovative core-functionality of CBSC's state-of-the-art cardiac event monitor

更新以提供设备改进,同时保持CBSC最先进的心脏事件监视器的创新核心功能

ESCONDIDO, CA / ACCESSWIRE / December 14, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced today that the company has entered the Beta testing phase for its updated My-Cam cardiac event monitoring device. The updated design provides improved power consumption, enhanced lead wire shielding, improved signal quality, and a more cost-effective part sourcing while maintaining its core functionality of being a state-of-the-art auto-trigger device.

加利福尼亚州埃斯孔迪多/ACCESSWIRE/2021年12月14日/CB Science,Inc.(场外粉色股票代码:CBSC)(以下简称“CBSC”或“公司”)今天宣布,该公司已进入其最新的My-Cam心脏事件监测设备的Beta测试阶段。更新后的设计提供了更高的功耗、更强的引线屏蔽、更高的信号质量,以及更具成本效益的部件采购,同时保持了其作为最先进的自动触发设备的核心功能。

As demand for the My-Cam device continues to grow throughout CB Scientific's subsidiaries and partners, CBSC's commitment to the manufacturing process, both domestically and internationally, will ensure that the company will be able to meet customer demand throughout the current supply chain crisis and beyond. The company anticipates that upon the completion of successful Beta testing, it will move into Pre-production testing (also known as User Acceptance Testing) in the coming weeks.

随着CB Science的所有子公司和合作伙伴对My-Cam设备的需求持续增长,CBSC对国内和国际制造工艺的承诺将确保该公司能够在当前的供应链危机期间乃至以后满足客户的需求。该公司预计,在Beta测试成功完成后,将在未来几周内进入生产前测试(也称为用户验收测试)。

As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

随着更多新情况的出现,CB Science,Inc.计划通过新闻稿和监管文件及时发布公告,使其股东、行业参与者和公开市场随时了解情况。

About CB Scientific, Inc.
CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

关于CB Science,Inc.
CB Science,Inc.通过其国内和国际子公司,在非侵入性非侵入性心脏监测领域提供创新的产品和服务。我们的FDA和CE批准的EKG设备、基于云的交互式采集软件以及适用于iOS和Android平台的智能手机应用程序为有心律异常风险的患者提供了更好的遵从性,并为医生提供了更准确的信息。

Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

公司联系信息:
电话:(888)225-0870
电子邮件:General Queries:info@cbSciences ficinc.com
投资者咨询:Robert Hesse-dorchco.bh@gmail.com
关注CBSC:Twitter、Facebook、Instagram、LinkedIn、YouTube和时事通讯

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

这一信息披露可能包含“1995年私人证券诉讼法案”所涵盖的前瞻性陈述。这些前瞻性陈述涉及推出或增强我们的服务和产品的计划和时间,有关未来市场状况、供需状况的陈述,以及本新闻稿中包含的其他预期、意图和计划,这些都不是历史事实,涉及风险和不确定因素。我们对未来收入的预期取决于我们开发和供应产品和服务的能力,这些产品和服务可能不是我们今天生产的,而且符合规定的规格。在本新闻稿中使用的“计划”、“预期”、“相信”以及类似的表述通常代表前瞻性陈述。这些声明反映了我们目前的期望。它们受到许多风险和不确定性的影响,包括但不限于技术的变化和无处不在的市场的变化。本新闻稿包括1933年“证券法”第27A节和1934年“证券法”第27E节的含义内的前瞻性陈述。本新闻稿中包含的非历史事实的陈述可能被视为前瞻性陈述。投资者需要注意的是,前瞻性陈述本质上是不确定的。由于某些风险和不确定因素,包括但不限于获得融资以及监管机构和股东对预期行动的批准的能力,实际业绩和结果可能与本文预测或建议的大不相同。

SOURCE: CB Scientific, Inc.

资料来源:CB Science,Inc.


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。

回到顶部